Abstracts

Rationale: Clobazam have been established as valuable add-on medication for refractory epilepsy. Clobazam have been used in our institution for more than 15 years, with benefit observe in many patients. Methods: Retrospective chart review of patient who were treated with Clobazam between 2008 and 2017 for treatment of intractable epilepsy. The following information were collected; age, sex, seizures type and frequency and per month pre and post Clobazam. Information were entered in Redcap database. Results: 121 patients were reviewed to evaluate the response of seizures to the use of Clobazam. Age mean is 8 years old; male (73) and female (48). several seizure types were identified ; GTC, Myoclonic. atonic , infantile spasm, complex partial seizure evolving to secondarily generalized ,complex partial seizure not evolving to secondarily generalized, simple partial seizure evolving to secondarily generalized ,simple partial seizure not evolving to secondarily generalized and absence seizure.The median decrease in the average number of monthly seizures for all patients was 30. This shows a significant decrease with a p. value 0.0001. The seizures with highest response to Clobazam are myoclonic, atonic, infantile spasm more than generalized atonic clonic and partial seizures. The median decrease in the average monthly seizures following Clobazam was 30 among males and 40 among females with s p. value = 0.7143, with no significant association between the sex and the decrease of average monthly seizures following Clobazam.Clobazam presented a stronger effect on younger children compared to the age above 15 (Spearman’s correlation coefficient was calculated and yielded a value of 0.2273 (p. value 0.0370) Conclusions: Our study confirmed the efficacy of Clobazam for treatment of intractable epilepsy. Clobazam efficacy more superior in generalized seizures type i.e. myoclonic, atonic, infantile spasm than GTC and partial seizures. Younger children response better than older children.